Mir, O., Cropet, C., Toulmonde, M., Cesne, A. L., Molimard, M., Bompas, E., Cassier, P., Ray-Coquard, I., Rios, M., Adenis, A., Italiano, A., Bouché, O., Chauzit, E., Duffaud, F., Bertucci, F., Isambert, N., Gautier, J., Blay, J., Pérol, D., & , (n.d.). pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet oncology, 17(5), 632–641. http://access.bl.uk/ark:/81055/vdc_100032015727.0x00000d